275 related articles for article (PubMed ID: 26809842)
1. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Wu RR; Zhang FY; Gao KM; Ou JJ; Shao P; Jin H; Guo WB; Chan PK; Zhao JP
Mol Psychiatry; 2016 Nov; 21(11):1537-1544. PubMed ID: 26809842
[TBL] [Abstract][Full Text] [Related]
2. [Metformin treatment of antipsychotic-induced dyslipidemia: analysis of two randomized, placebo-controlled trials].
Yang Y; Wang X; Kang D; Long Y; Ou J; Guo W; Zhao J; Wu R
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1128-1136. PubMed ID: 31857506
[TBL] [Abstract][Full Text] [Related]
3. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
[TBL] [Abstract][Full Text] [Related]
4. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Wu RR; Jin H; Gao K; Twamley EW; Ou JJ; Shao P; Wang J; Guo XF; Davis JM; Chan PK; Zhao JP
Am J Psychiatry; 2012 Aug; 169(8):813-21. PubMed ID: 22711171
[TBL] [Abstract][Full Text] [Related]
5. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Wang M; Tong JH; Zhu G; Liang GM; Yan HF; Wang XZ
Schizophr Res; 2012 Jun; 138(1):54-7. PubMed ID: 22398127
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
7. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
8. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Jiang WL; Cai DB; Yin F; Zhang L; Zhao XW; He J; Ng CH; Ungvari GS; Sim K; Hu ML; Zheng W; Xiang YT
Transl Psychiatry; 2020 Apr; 10(1):117. PubMed ID: 32327628
[TBL] [Abstract][Full Text] [Related]
11. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
[TBL] [Abstract][Full Text] [Related]
12. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
13. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
[TBL] [Abstract][Full Text] [Related]
14. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Siskind D; Friend N; Russell A; McGrath JJ; Lim C; Patterson S; Flaws D; Stedman T; Moudgil V; Sardinha S; Suetani S; Kisely S; Winckel K; Baker A
BMJ Open; 2018 Mar; 8(3):e021000. PubMed ID: 29500217
[TBL] [Abstract][Full Text] [Related]
15. Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Chiu CC; Lu ML; Huang MC; Chen PY; Lin YK; Lin SK; Chen CH
PLoS One; 2016; 11(12):e0168347. PubMed ID: 27973619
[TBL] [Abstract][Full Text] [Related]
16. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
Miller LJ
Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
[TBL] [Abstract][Full Text] [Related]
17. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
[TBL] [Abstract][Full Text] [Related]
18. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
19. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
Zheng W; Li XB; Tang YL; Xiang YQ; Wang CY; de Leon J
J Clin Psychopharmacol; 2015 Oct; 35(5):499-509. PubMed ID: 26280837
[TBL] [Abstract][Full Text] [Related]
20. Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Adeneye AA; Agbaje EO; Olagunju JA
Indian J Exp Biol; 2011 May; 49(5):332-8. PubMed ID: 21615056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
